TapImmune to Present at World Vaccine & Immunotherapy Congress West Coast
JACKSONVILLE, Fla., Nov. 17, 2017 /PRNewswire/ — TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced its Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, “Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system,” at the World Vaccine & Immunotherapy Congress West Coast, held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.
The presentation will highlight data on the Company’s proprietary DNA vaccine technology, PolyStart™, and its use in driving DNA vaccine antigen expression and presentation to enable increased visibility of tumor cells to the immune system and more effectively target the cytotoxic activity of CD8+ killer T-cells.
Dr. Wilson and Dr. Florkiewicz will be available for one-on-one meetings at the conference.
TapImmune Event Details:
Title: Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system
Date: Thursday, November 30, 2017
Time: 3:45 p.m. (Pacific Time)
Location: Loews Coronado Bay Resort, San Diego, CA
About TapImmune Inc.
TapImmune Inc. is a leader in the TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company’s peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company’s technologies may be used as stand-alone medications or in combination with other treatment modalities.
For additional information, please call toll free at (904) 862-6490 or visit: tapimmune.com
To receive future press releases via email, please visit: https://tapimmune.com/investors/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-present-at-world-vaccine–immunotherapy-congress-west-coast-300558975.html
SOURCE TapImmune Inc.